Skip to main content
TipRanks
Go Ultimate75% OFF

QHSLab (USAQ) AI Stock Analysis

37 Followers
USAQ

QHSLab

(Other OTC:USAQ)

Select Model
Rating:65Neutral
Price Target:$0.39▲(7.38% Upside)
Action:reiterated
Date:11/13/26

The score is supported primarily by a strong, low-debt balance sheet and low P/E ratio. These strengths are offset by negative cash flow, weakening earnings momentum, and mixed technical conditions, including negative MACD and trading below the 200-day moving average.

Positive Factors
De-risked balance sheetNear-zero debt and positive equity materially improve financial flexibility, reducing the burden of interest and refinancing obligations. This gives QHSLab more capacity to absorb operating volatility and support its business without relying heavily on external financing over the next several quarters.
Negative Factors
Weak cash conversionNegative operating and free cash flow alongside positive net income raises a durable earnings-quality concern. The divergence means reported profits are not currently translating into cash that can fund operations, reduce financial risk, or support investment, limiting confidence in profit sustainability.

QHSLab (USAQ) vs. SPDR S&P 500 ETF (SPY)

-50%0%50%100%150%200%250%300%USAQ+46.99%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$5.52M
Dividend Yield
―
Average Volume (3M)
5,146
Price to Earnings (P/E)
9.0
Beta (1Y)
1.93
Revenue Growth
13.13%
EPS Growth
―
Country
US
Employees
12
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

QHSLab Business Overview & Revenue Model

Company Description

QHSLab, Inc. is a company operating in the medical technology and Software-as-a-Service (SaaS) sectors. Its core focus is on advancing value-based healthcare, medical informatics, and personalized medicine driven by algorithms. The firm also develops...

QHSLab Financial Statement Overview

Summary

Strong balance sheet with minimal debt, positive equity, and 51.2% ROE supports the score. However, declining earnings momentum, negative EBIT, and approximately $237,000 of negative operating and free cash flow materially reduce financial quality.

Income Statement

72Positive

Balance Sheet

80Positive

Cash Flow

42Neutral
Financial statement breakdown
BreakdownTTMMar 2026Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue2.96M2.69M2.13M1.41M1.24M1.41M
Gross Profit1.98M1.81M1.36M793.61K619.52K670.75K
EBITDA571.66K785.56K352.39K-91.29K-434.60K-487.63K
Net Income437.55K457.42K-259.24K-468.36K-996.00K-770.18K
Balance Sheet
Total Assets1.75M2.17M1.80M1.68M1.96M2.21M
Cash, Cash Equivalents and Short-Term Investments190.46K636.16K157.17K51.58K178.69K286.86K
Total Debt97.82K20.00K1.72M1.78M1.68M1.30M
Total Liabilities247.11K546.08K2.41M2.06M1.88M1.38M
Stockholders Equity1.51M1.62M-607.76K-375.62K76.25K824.07K
Cash Flow
Free Cash Flow-236.96K178.12K142.44K-159.63K-388.11K-509.31K
Operating Cash Flow-236.96K178.12K142.44K-159.63K-350.99K-354.74K
Investing Cash Flow0000-37.12K-154.57K
Financing Cash Flow269.03K300.87K-36.85K32.52K279.95K701.82K

QHSLab Technical Analysis

Technical Analysis SentimentPositive
Last Price0.37

Price Trends

50DMA0.35Positive
100DMA0.33Positive
200DMA0.46Negative

Market Momentum

MACD-0.01Negative
RSI55.60Neutral
STOCH52.56Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For USAQ, the sentiment is Positive. The current price of 0.37 is above the 20-day moving average (MA) of 0.32, above the 50-day MA of 0.35, and below the 200-day MA of 0.46, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 55.60 is Neutral, neither overbought nor oversold. The STOCH value of 52.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for USAQ.

QHSLab Risk Analysis

QHSLab disclosed 43 risk factors in its most recent earnings report. QHSLab reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Our stock price may be adversely impacted by natural disasters (whether or not caused by climate change), unusually adverse weather conditions, pandemic outbreaks, terrorist acts, conflicts between nations and terrorist organizations, and the response of the governments of the countries affected by such occurrences.Q4, 2023
2.We are highly leveraged and we may need additional financing.Q4, 2023
3.Our ability to finance our business may be materially adversely affected by global geopolitical conditions including those resulting from the ongoing Russia-Ukraine conflict, the Israel-Hamas conflict and efforts by terrorist organizations to disrupt global shipping patterns.Q4, 2023

QHSLab Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

USAQ against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
USAQUSAQ65Neutral$5.51M8.9728.18%―13.13%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
NUWENUWE47Neutral$2.65M-0.00-408.34%―10.28%95.85%
AEMDAEMD44Neutral$8.49M-0.50-141.22%――90.69%

* Healthcare Sector Average

Performance Comparison

0%200%400%USAQNUWEAEMDBBLGDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
USAQ and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
USAQQHSLab, Inc.0.370.20124.54%
NUWENuwellis, Inc.4.90-767.48-99.37%
AEMDAethlon5.29-14.96-73.88%
BBLGBone Biologics Corp0.33-1.30-80.06%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026